Get the Stockscreener App
3.80
3.26%
0.12
After Hours:
3.95
0.15
+3.95%
Sab Biotherapeutics Inc stock is traded at $3.80, with a volume of 710.39K.
It is up +3.26% in the last 24 hours and down -1.30% over the past month.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
See More
Previous Close:
$3.68
Open:
$3.8
24h Volume:
710.39K
Relative Volume:
1.28
Market Cap:
$267.05M
Revenue:
$114.70K
Net Income/Loss:
$-12.82M
P/E Ratio:
-1.4214
EPS:
-2.6735
Net Cash Flow:
$-45.71M
1W Performance:
+9.20%
1M Performance:
-1.30%
6M Performance:
+22.58%
1Y Performance:
+127.54%
1-Day Range:
$3.63
$3.98
1-Week Range:
$3.45
$3.98
52-Week Range:
$1.60
$6.60
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Name
Sab Biotherapeutics Inc
Sector
Industry
Phone
305-845-2813
Address
777 W 41ST ST, MIAMI BEACH
Compare SABS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.80 | 258.61M | 114.70K | -12.82M | -45.71M | -2.6735 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-26 | Initiated | Rodman & Renshaw | Buy |
| Dec-19-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Initiated | Leerink Partners | Outperform |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Oct-09-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Nov-05-21 | Initiated | Chardan Capital Markets | Buy |
View All
Sab Biotherapeutics Inc Stock (SABS) Latest News
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - Investing News Network
SAB Biotherapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
SAB BIO plans May 12 morning webcast on first-quarter results - Stock Titan
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142 - TipRanks
SAB Biotherapeutics (SABS) sets 5-year, $36M post-approval SAB-142 manufacturing pact - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
Millennium entities disclose 3.43M shares in SAB Biotherapeutics (SABS) - Stock Titan
SAB Biotherapeutics (SABS) Expected to Announce Earnings on Friday - MarketBeat
SAB Biotherapeutics (NASDAQ: SABS) outlines 2026 virtual annual meeting and board elections - Stock Titan
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Expands By 19.8% - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Shares Down 1.4%Here's What Happened - MarketBeat
Emergent Inches Lower on New Deal with SAB - Baystreet.ca
Emergent BioSolutions (EBS) Secures $50M Agreement for SAB-142 D - GuruFocus
Emergent BioSolutions Wins $50 Million SAB Biotherapeutics Manufacturing Contract - citybiz
Type 1 diabetes candidate SAB-142 gets $50M manufacturing pact - Stock Titan
Guggenheim Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
SABS Price Today: SAB Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating - Moomoo
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results - TipRanks
SAB Biotherapeutics presents Phase 1 SAB-142 data showing C-peptide preservation, improved TIR - TradingView
[8-K] SAB Biotherapeutics, Inc. Reports Material Event - Stock Titan
SAB BIO Presents Additional Clinical and Mechanistic Data - GlobeNewswire
In 4 adults with type 1 diabetes, SAB-142 lifted time in range to 85% - Stock Titan
SAB Biotherapeutics (SABS) Stock: Why Competitive Advantage (Trend Strengthens) 2026-04-20Diversification - Xã Vĩnh Công
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress - Sahm
SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes - National Today
New type 1 diabetes data from SAB-142 heads to Brisbane meeting - Stock Titan
SAB BIO to Present Additional Data Supporting the Unique - GlobeNewswire
Breakouts Watch: Whats the profit margin of SAB Biotherapeutics Inc Equity WarrantWatch List & AI Powered Trade Plan Recommendations - baoquankhu1.vn
SABS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Published on: 2026-04-12 12:29:27 - baoquankhu1.vn
Investment Report: Will SAB Biotherapeutics Inc outperform during market rallies2026 PostEarnings & High Win Rate Trade Tips - baoquankhu1.vn
SABS Options Volatility — NASDAQ:SABS - TradingView
Aug Chart Watch: Will SAB Biotherapeutics Inc stock recover after earnings2026 Sector Review & Real-Time Volume Triggers - baoquankhu1.vn
How does SAB Biotherapeutics (SABS) Stock react to Fed policy | Price at $3.75, Down 2.09%Quantitative Analysis - Newser
EV Market: Will SAB Biotherapeutics Inc outperform during market ralliesWeekly Risk Report & Precise Trade Entry Recommendations - baoquankhu1.vn
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Trading Action: Is Sinclair Incs growth already priced inQuarterly Growth Report & Weekly Hot Stock Watchlists - baoquankhu1.vn
Insider Trends: Is SAB Biotherapeutics Inc being accumulated by smart moneyMarket Risk Report & Stock Portfolio Risk Management - baoquankhu1.vn
Trading Recap: Is HADPP showing insider buyingQuarterly Market Summary & Growth Focused Entry Point Reports - baoquankhu1.vn
Is SAB Biotherapeutics (SABS) Stock Testing Support | Price at $3.89, Up 0.26%Trend Signals - Newser
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated at Rodman & Renshaw - MarketBeat
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating By Investing.com - Investing.com Canada
Rodman & Renshaw initiates SAB Biotherapeutics stock with buy rating - Investing.com
SABSW SEC FilingsSAB BIOTHERAPEUTICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Up 21.1% in March - MarketBeat
Published on: 2026-03-30 20:34:02 - baoquankhu1.vn
Published on: 2026-03-27 23:19:55 - baoquankhu1.vn
Institution Moves: Is SAB Biotherapeutics Inc stock a smart retirement pickIPO Watch & Pattern Based Trade Signal System - baoquankhu1.vn
Sab Biotherapeutics Inc Stock (SABS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):